MedPath

A clinical trial to study the effect of drug Ayakantha Chendhooram for patients having low back pain

Phase 2
Recruiting
Conditions
Vathasthambam (Sciatica)
Registration Number
CTRI/2017/05/008575
Lead Sponsor
GOVT SIDDHA MEDICAL COLLEGE
Brief Summary

This is a single single arm open clinical trial to study the safety and efficacy of Siddha trial drug Ayakantha chendhooram. The trial drug is given 100 milli grams twice a day for 48 days. Clinical trial is conducted after conducting Preclinical toxicity study. The trial drug Ayakantha chendhooram is mentioned in Nasakanda venba . During the trial all the study related data will be recorded and documented. After the completion of trial all the data will be analysed statistically.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
20
Inclusion Criteria
  • patients having pain in back or leg that is worsened while sitting 2.burning or tingling sensation down the leg, weakness,numbness,difficulty moving the leg or foot 3.A constant pain on one side of the back 4.
  • Patients having positive SLR Test.
Exclusion Criteria

1.Patients of age below 18 above 60 years 2.Fracture of vertebral 3.Dislocation of vertebral 4.Deformities and congenital defects 5.Known case of TB of spine 6.Known case of neoplasam of spine pregnancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Out come of treatment is assessed by reduction in symptoms and this will be considered as successive measures48 Days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Arignar Anna Government Hospital of Indian Medicine and Homeopathy

🇮🇳

Chennai, TAMIL NADU, India

Arignar Anna Government Hospital of Indian Medicine and Homeopathy
🇮🇳Chennai, TAMIL NADU, India
Dr KR Muthumari
Principal investigator
9629291574
drmuthumarikrishnan@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.